Widely used:Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
₹1,496 Cr
P/E Ratio
28.59
P/B Ratio
6.53
Industry P/E
37.87
Debt to Equity
0
ROE
14.02 %
ROCE
17.72 %
Div. Yield
0.89 %
Book Value
34.49
EPS
10.54
CFO
₹168.26 Cr
EBITDA
₹134.39 Cr
Net Profit
₹104.92 Cr
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Jagsonpal Pharma
| -7.93 | 3.57 | -6.67 | 59.86 | 22.72 | 81.82 | 34.22 |
|
BSE Healthcare
| -6.54 | 1.91 | 1.42 | 18.70 | 20.14 | 22.31 | 10.08 |
|
BSE Small Cap
| -13.49 | 1.63 | -3.38 | 0.28 | 18.33 | 33.99 | 15.77 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Jagsonpal Pharma
| 55.10 | 4.33 | 108.36 | 122.10 | 178.95 | -18.41 | -19.54 |
|
BSE Small Cap
| 29.04 | 47.52 | -1.80 | 62.77 | 32.11 | -6.85 | -23.41 |
|
BSE Healthcare
| 43.09 | 36.97 | -12.10 | 20.87 | 61.45 | -3.55 | -5.89 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | P/E Ratio | ROE |
|---|---|---|---|---|
| 421.00 | 6,841.28 | 24.93 | 12.5 | |
| 5,082.00 | 8,400.95 | 35.51 | 43.77 | |
| 647.05 | 6,319.25 | 71.58 | 4.01 | |
| 649.90 | 6,082.74 | 22.57 | 12.68 |
No Review & Analysis are available.
Jagsonpal Pharmaceuticals Limited engages in the manufacturing, selling, and trading of pharmaceutical products and active pharmaceutical ingredients in India and internationally. It offers pharmaceutical formulations and products in the areas of... gynaecology, orthopaedics, dermatology, and paediatrics. The company provides drugs in the form of tablets, softgels, injections, capsules, and syrups. It serves health care professionals and government institutions. Jagsonpal Pharmaceuticals Limited was incorporated in 1978 and is based in Gurugram, India. Read more
Incorporated
1978
Chairman
Harsha Raghavan
Managing Director
Manish Gupta
Group
Jagsonpal
Headquarters
New Delhi, Delhi
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Jagsonpal Pharmaceuticals Ltd stood at ₹ 258 Cr as on 31-Dec-24
The share price of Jagsonpal Pharmaceuticals Ltd is ₹224.96 (NSE) and ₹225.20 (BSE) as of 30-Apr-2025 IST. Jagsonpal Pharmaceuticals Ltd has given a return of 22.72% in the last 3 years.
Jagsonpal Pharmaceuticals Ltd has a market capitalisation of ₹ 1,496 Cr as on 30-Apr-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Jagsonpal Pharmaceuticals Ltd is 6.53 times as on 30-Apr-2025, a 29% premium to its peers’ median range of 5.06 times.
The P/E ratio of Jagsonpal Pharmaceuticals Ltd is 28.59 times as on 30-Apr-2025, a 25% discount to its peers’ median range of 37.87 times.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Jagsonpal Pharmaceuticals Ltd and enter the required number of quantities and click on buy to purchase the shares of Jagsonpal Pharmaceuticals Ltd.
Jagsonpal Pharmaceuticals Limited engages in the manufacturing, selling, and trading of pharmaceutical products and active pharmaceutical ingredients in India and internationally. It offers pharmaceutical formulations and products in the areas of gynaecology, orthopaedics, dermatology, and paediatrics. The company provides drugs in the form of tablets, softgels, injections, capsules, and syrups. It serves health care professionals and government institutions. Jagsonpal Pharmaceuticals Limited was incorporated in 1978 and is based in Gurugram, India.
The prominent promoters of Jagsonpal Pharmaceuticals Ltd. are
| Name of promoters | Holding percentage |
|---|---|
|
ARESKO PROGRESSIVE PRIVATE LIMITED |
20.08%
|
|
INFINITY HOLDINGS SIDECAR I |
17.9%
|
|
INFINITY HOLDINGS |
16.62%
|
|
INFINITY PORTFOLIO HOLDINGS |
8.61%
|
|
RAJPAL SINGH KOCHHAR |
4.56%
|
The chairman of the company is Harsha Raghavan, and the managing director is Manish Gupta.
There is no promoter pledging in Jagsonpal Pharmaceuticals Ltd.
Some of the close peers are:
| Company | Market Cap(₹ Cr) |
|---|---|
|
8,423
|
|
|
6,920
|
|
|
6,675
|
|
|
6,029
|
| Jagsonpal Pharmaceuticals Ltd. | Ratios |
|---|---|
|
Return on equity(%)
|
18.52
|
|
Operating margin(%)
|
15.3
|
|
Net Margin(%)
|
20.01
|
|
Dividend yield(%)
|
0.88
|
Yes, TTM profit after tax of Jagsonpal Pharmaceuticals Ltd was ₹52 Cr.
₹-2.50
(
